Free tool
FAERS Monitor: Cardamyst
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 218571 or its brand name (Cardamyst, Etripamil). Reports on generic versions are filed under their own applications.
Reports
11
Serious
2
18% of reports
Hospitalization
2
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nasal discomfort4
- oropharyngeal pain3
- drug ineffective2
- hypertension2
- hypotension2
- nasal dryness2
- rhinalgia2
- wrong technique in product usage process2
- contraindicated product prescribed1
- drug effect less than expected1
- dysgeusia1
- epistaxis1
- heart rate increased1
- inappropriate schedule of product administration1
- intercepted product prescribing error1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2026 | 11 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,148 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| intercepted product prescribing error | 1 | 1444.5 | 222.7 | 360 |
| rhinalgia | 2 | 1392.5 | 397.3 | 1,563 |
| contraindicated product prescribed | 1 | 1139.3 | 175.7 | 284 |
| nasal discomfortSignal | 4 | 965.2 | 441.5 | 2,949 |
| nasal dryness | 2 | 610.4 | 174.2 | 684 |
| drug effect less than expected | 1 | 129.0 | 19.9 | 31 |
| oropharyngeal painSignal | 3 | 62.0 | 23.6 | 125 |
| dysgeusia | 1 | 25.7 | 4.0 | 5 |
| epistaxis | 1 | 25.6 | 3.9 | 5 |
| heart rate increased | 1 | 19.3 | 3.0 | 4 |
| hypotension | 2 | 19.1 | 5.4 | 19 |
| wrong technique in product usage process | 2 | 18.9 | 5.4 | 19 |
| hypertension | 2 | 18.1 | 5.2 | 18 |
| inappropriate schedule of product administration | 1 | 10.6 | 1.6 | 2 |
| drug ineffective | 2 | 2.9 | 0.8 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.